Immunocore Appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer
Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, today announces that Dr Mohammed Dar has been appointed as Head of Clinical Development and Chief Medical Officer, effective April 16, 2019.
Commenting on the appointment, Bahija Jallal Chief Executive Officer of Immunocore, said: “Immunocore is approaching a crucial point in the Company’s development, with our lead product candidate, tebentafusp, moving through pivotal studies. Mohammed has a complete breadth of experience in leading clinical teams through early and late stage development. We’re delighted to have such a distinguished physician, scientist and industry leader join us as we progress tebentafusp and our other promising candidates through clinical development.”
Mohammed will be responsible for clinical, operational, biostatistics and medical affairs functions across all therapeutic areas. This includes Immunocore’s wholly-owned lead programme, tebentafusp, in addition to the growing pipeline in oncology, infectious diseases, which includes target indications such as Hepatitis B and HIV, and autoimmune diseases.
“The potential of Immunocore’s unparalleled science and TCR platform is very impressive,” said Mohammed Dar, Head of Clinical Development and Chief Medical Officer of Immunocore. “I am thrilled to have joined Immunocore at such an exciting time for the Company and I look forward to working with the scientific leadership team to drive this compelling science forward.”
Mohammed has over 15 years of pharmaceutical industry experience in the field of oncology. Before joining Immunocore, Mohammed was Vice President, Clinical Development Oncology, R&D at MedImmune (AstraZeneca) and spent 10 years at GSK in roles of increasing responsibility focused on early clinical development in oncology. While at MedImmune, he led the clinical trials and teams supporting the approval of anti-PD-L1 checkpoint inhibitor, durvalumab, and anti-CD22 immunotoxin, moxetumomab. Mohammed received his Bachelor’s Degree in Chemistry from the University of North Carolina at Chapel Hill and his M.D. and Internal Medicine training from Duke University School of Medicine. He went on to complete his Fellowship in Hematology and Oncology at the National Cancer Institute.
Mohammed joins two other world-class development leaders at Immunocore, Mark Moyer, Head of Regulatory, Safety and Project Management, and Koustubh Ranade, Head of Translational Medicine. Mark is one of the most experienced immuno-oncology development leaders with over 30 years of drug development experience at companies including Bristol-Myers Squibb (BMS) and Sanofi. As regulatory oncology head at BMS, he was accountable for 37 BLAs/MAAs, including for nivolumab, ipilimumab and elotuzumab. Koustubh was most recently Vice President of Translational Medicine at MedImmune for all therapeutic areas, where he contributed to four product approvals, including durvalumab. With over three decades of research experience at Genentech, BMS, Stanford and NIH, Koustubh is a co-inventor on many patents, has published extensively in top-tier journals and has edited a book on genomics.
Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class
biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and the lead programme, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.
Louise Conlon, External Affairs and Brand Communications Manager
T: +44 (0) 1235 438600
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Melissa Gardiner
T: +44 (0)203 709 5700
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Defence Unlimited International Corp. is Hiring Veterans17.7.2019 20:58:00 CEST | Press release
Defence Unlimited International is one of the fastest growing companies operating within the defence and security space. Defence Unlimited International has adopted a unique outsourced model which integrates multiple partners both individual and corporate, on its projects. This has enabled it to offer and deliver to its clients best of breed bespoke solutions. Whilst Defence Unlimited is pursuing its drive towards achieving a more global footprint in its operations, the founder, Edward Banayoti firmly reiterates the continued commitment of the company to its existing strategy of identifying and successfully deploying experienced individuals that have served in the military. Individuals and teams with such experience can offer invaluable value added within projects Defence Unlimited are active in or are in the process of executing. "We take pride in our track record of offering numerous opportunities to Veterans who have served their country, giving such individuals who have heeded a pa
Temenos Acquires a SaaS-based, Patented, Explainable AI (XAI) Platform to Accelerate its AI Roadmap and Expertise17.7.2019 16:22:00 CEST | Press release
Contact information Media Contacts Jessica Wolfe Temenos Global Public Relations Tel: +1 610 232 2793 Email : email@example.com Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos Tel: +44 20 7680 6550 Email: firstname.lastname@example.org
Gartner Names Airship a Leader, Positioned Highest in Execution and Furthest in Vision in the Magic Quadrant for Mobile Marketing Platforms17.7.2019 15:59:00 CEST | Press release
Customer engagement company Airship today announced that it has been named a Leader by Gartner, Inc. in its 2019 Magic Quadrant for Mobile Marketing Platforms1. Among 18 vendors evaluated, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision. A complimentary copy of the full report is available from Airship. “We believe Gartner’s positioning of Airship validates our unique ability to deliver innovative, transformative digital customer experiences for the world’s leading brands,” said Brett Caine, CEO and president, Airship. “Airship delivers rich messages with pinpoint accuracy on whatever channel is most convenient and effective for the customer. Today’s customer expects proactive information and real-time response, and Airship is the essential component that makes it all possible.” According to Gartner, “Globally, consumers spend more of their time on smartphones than on desktops, laptops or tablets. This broad and rapid consumer a
GSMA Signs £38 Million Funding Partnership With the Department of International Development17.7.2019 15:02:00 CEST | Press release
The GSMA today announced that it has signed a thirty-eight million-pound partnership with the UK’s Department for International Development (DFID). The ‘Partnership for Inclusion, Innovation and Scale’ will provide funding for the GSMA’s Mobile for Development work on digital inclusion, digital identity, energy, water, sanitation and the reduction of the mobile gender gap. It will also include two new areas of focus: disability and climate. “This landmark partnership with DFID reinforces the joint power and potential of the private and public sectors working together and ensures that we will continue our crucial role of stimulating digital innovation to deliver both sustainable business and large-scale socio-economic impact for the underserved,” said Mats Granryd, Director General, GSMA. “This project reinforces our commitment to supporting the UN’s Sustainable Development Goals and using the power of technology to reduce global inequalities.” Inclusion, Innovation and Scale The partne
Gilead Sciences Announces Changes to Senior Leadership Team17.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function. Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization. “Gregg has been a valued leader at Gilead for nearly 20
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company17.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation. “Over the past nine years, John’s scientific contributions and le